Autoantibodies against tumour-associated proteins can identify tumours that are too small to secrete a sufficiently large amount of protein biomarkers for detection, and therefore they are more rapidly detected in serum than, for example, the biomarker CA125. This evidence concerns the gene MUC16 and neoplasm.